Testosterone replacement therapy was originally developed for older men with classical hypogonadism. In recent years, a different demographic has driven much of the growth in prescriptions: men in their 20s and 30s seeking improved mood, energy, muscle mass, and libido. TRT prescriptions in the United States rose from 7.3 million in 2019 to more than 11 million in 2024, and a significant share of that growth is in younger patients (Nature, 2026).
The research on this group is thinner than for older men, and the calculus around benefit and risk is genuinely different. Here is what we know.
Why Younger Men Are Seeking TRT
Several trends are converging. Average testosterone levels in American men have declined over the past several decades, even when controlling for age, weight, and lifestyle (NPR, 2025). Awareness of low testosterone symptoms has grown thanks to social media and direct to consumer marketing. Telehealth has made TRT more accessible than ever, with online providers able to write prescriptions quickly after a single lab draw. Lifestyle factors that suppress testosterone, including poor sleep, obesity, stress, and exposure to endocrine disrupting chemicals, are widespread in this age group.
What the Research Shows
Most clinical trials supporting current TRT guidelines were conducted on men older than 40, and many of the largest, including TRAVERSE, focused on patients in their 50s and beyond. The safety and benefit data we have do not necessarily transfer cleanly to a 28 year old (The Conversation, 2025).
What we do know: TRT consistently improves libido and erectile function in men with confirmed low testosterone, including in younger patients, and this is the most well established benefit across all age groups. A 2019 JAMA Psychiatry meta analysis found testosterone therapy was associated with reduced depressive symptoms in men with hypogonadism (Voy, TRT side effects review), with effect sizes that were modest but consistent. TRT increases lean mass and reduces fat mass in men with low testosterone, though the effect is real but smaller than the gains often promoted in fitness marketing. Evidence for energy and cognition improvements is weaker, with some men reporting meaningful improvement but controlled trials showing only modest effects.
Fertility. This is where younger men face a unique problem. Exogenous testosterone suppresses the body's natural production and dramatically reduces sperm count. The effect is usually reversible, but recovery can take months and is not guaranteed (Voy, TRT side effects review; The Conversation, 2025).
The Fertility Issue
For a 30 year old who has not had children and may want them, starting TRT without a clear plan for fertility preservation is a significant decision. Standard approaches include sperm banking before therapy, or co administration of HCG or other agents that maintain testicular function.
Reputable providers raise fertility explicitly before prescribing. Be cautious of any clinic that does not.
Long Term Risk Uncertainty
Most TRT safety data, including cardiovascular and prostate outcomes, comes from studies in older men. For younger patients starting TRT in their 20s and 30s and potentially staying on for decades, we simply do not have long term data. Some clinicians worry about cumulative effects on cardiovascular health, polycythemia, and the prostate over 30 or 40 years of therapy. Others note that natural hypogonadism left untreated also carries long term risks.
The honest answer is that the long term risk profile of starting TRT young is still being established.
When TRT Is Appropriate for Younger Men
Most endocrinologists and urologists agree TRT is appropriate for younger men when testosterone is clinically low on at least two morning blood draws, symptoms are present and meaningful, reversible causes have been investigated and addressed (including weight, sleep, stress, alcohol use, and medications that suppress testosterone), a fertility plan is in place if the patient may want children, and the patient understands they may be on therapy for life.
